Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy

References

• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat.11(2), 97–107 (2004).
   PubMed Web of Science ®Google Scholar
• Hepatitis B vaccines. Wkly Epidemiol. Rec.84(40), 405–419 (2009).
   PubMedGoogle Scholar
• Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin. Liver Dis.14(1), 1–21, VII (2010).
   PubMedGoogle Scholar
• Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev.28, 112–125 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta K, Cooper C. A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R. D.9(3), 137–145 (2008).
   PubMed Web of Science ®Google Scholar
• Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin. Biol. Ther.7(11), 1731–1737 (2007).
   PubMed Web of Science ®Google Scholar
• Hepatitis B. World Health Organization Fact Sheet 204. World Health Organization, Geneva, Switzerland (2008).
   Google Scholar
• Goldstein ST, Zhou F, Hadler SC et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol.34(6), 1329–1339 (2005).
   PubMed Web of Science ®Google Scholar
• Shouval D. Hepatitis B vaccines. J. Hepatol.39(Suppl. 1), 7 (2003).
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol.45(4), 529–538 (2006).
   PubMed Web of Science ®Google Scholar
• Rots NY, Wijmenga-Monsuur AJ, Luytjes W et al. Hepatitis B vaccination strategies tailored to different endemicity levels: some considerations. Vaccine28(4), 893–900 (2010).
   PubMed Web of Science ®Google Scholar
• Shiffman ML. Management of acute hepatitis B. Clin. Liver Dis.14(1), 75–91; VIII-IX (2010).
   PubMed Web of Science ®Google Scholar
• Thomas DL, Di Bisceglie AM, Alter HJ, Terrault NA. Understanding the natural history of chronic HBV and HCV infections. J. Fam. Pract.59(Suppl. 4), S17–S22 (2010).
   PubMed Web of Science ®Google Scholar
• Chen DS. Toward elimination and eradication of hepatitis B. J. Gastroenterol. Hepatol.25(1), 19–25 (2010).
   PubMed Web of Science ®Google Scholar
• Girndt M, Litjens N. Unmet needs and new promises in hepatitis B vaccination for chronic kidney disease patients. European Nephrology4, 5 (2010).
   Google Scholar
• Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology1(5), 377–385 (1981).
   PubMed Web of Science ®Google Scholar
• Chen DS. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J. Hepatol.50(4), 805–816 (2009).
   PubMed Web of Science ®Google Scholar
• Floreani A, Baldo V, Cristofoletti M et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine22(5–6), 607–610 (2004).
   PubMed Web of Science ®Google Scholar
• Ni YH, Huang LM, Chang MH et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology132(4), 1287–1293 (2007).
   PubMed Web of Science ®Google Scholar
• Roznovsky L, Orsagova I, Kloudova A et al. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection38(5), 395–400 (2010).
   PubMed Web of Science ®Google Scholar
• Burgess MA, Rodger AJ, Waite SA, Collard F. Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomised study. Vaccine19(32), 4835–4841 (2001).
   PubMed Web of Science ®Google Scholar
• Gilbert C, Villa G, Klopfer S, Schodel F, Bhuyan P. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal predialysis and dialysis patients. Presented at: Infectious Disease Society Annual Meeting. Philadelphia, PA, USA, 29 October–1 November 2009.
   Google Scholar
• Vlassopoulos D. Recombinant hepatitis B vaccination in renal failure patients. Curr. Pharm. Biotechnol.4(2), 141–151 (2003).
   PubMedGoogle Scholar
• Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine21(31), 4604–4608 (2003).
   PubMed Web of Science ®Google Scholar
• Fazle Akbar SM, Furukawa S, Yoshida O et al. Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. J. Hepatol.47(1), 60–66 (2007).
   PubMed Web of Science ®Google Scholar
• Cruciani M, Mengoli C, Serpelloni G et al. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: a meta-analysis. Vaccine25(4), 709–718 (2007).
   PubMed Web of Science ®Google Scholar
• Products discontinued from the market since the publication of the 2000 CPS. In: Compendium of Pharmaceuticals and Specialties. CPS (Eds). Canadian Pharmacists Association, Canada (2010).
   Google Scholar
• Fabrizi F, Dixit V, Messa P, Martin P. Meta-analysis: levamisole improves the immune response to hepatitis B vaccine in dialysis patients. Aliment. Pharmacol. Ther.32(6), 756–762 (2010).
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y. Infections, vaccines and autoimmunity. Lupus18(13), 1127–1128 (2009).
   PubMed Web of Science ®Google Scholar
• Perez-Garcia R, Perez-Garcia A, Verbeelen D et al. AM3 (Inmunoferon) as an adjuvant to hepatitis B vaccination in hemodialysis patients. Kidney Int.61(5), 1845–1852 (2002).
   PubMed Web of Science ®Google Scholar
• Majano P, Roda-Navarro P, Alonso-Lebrero JL et al. AM3 inhibits HBV replication through activation of peripheral blood mononuclear cells. Int. Immunopharmacol.4(7), 921–927 (2004).
   PubMed Web of Science ®Google Scholar
• Bienzle U, Gunther M, Neuhaus R et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology38(4), 811–819 (2003).
   PubMed Web of Science ®Google Scholar
• Davis HL, Weeratna R, Waldschmidt TJ et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol.160(2), 870–876 (1998).
   PubMed Web of Science ®Google Scholar
• Sato Y, Roman M, Tighe H et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science273(5273), 352–354 (1996).
   PubMed Web of Science ®Google Scholar
• Madaan A. Heplisav. Drugs Future34(7), 5 (2009).
   Web of Science ®Google Scholar
• Sung JJ, Lik-Yuen H. HBV-ISS (Dynavax). Curr. Opin. Mol. Ther.8(2), 150–155 (2006).
   PubMedGoogle Scholar
• Higgins D, Marshall JD, Traquina P, Van Nest G, Livingston BD. Immunostimulatory DNA as a vaccine adjuvant. Expert Rev. Vaccines6(5), 747–759 (2007).
   PubMed Web of Science ®Google Scholar
• Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell. Immunol.167(1), 72–78 (1996).
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature374(6522), 546–549 (1995).
   PubMed Web of Science ®Google Scholar
• Martin-Orozco E, Kobayashi H, Van Uden J et al. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int. Immunol.11(7), 1111–1118 (1999).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Van Nest G, Smith B et al. A Phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine21(19–20), 2461–2467 (2003).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Dobson S, McNeil S et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine24(1), 20–26 (2006).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Diaz-Mitoma F, Martin T, De Boer AW. Immunogenicity and safety of an investigational hepatitis B vaccine. Presented at: Fifth Decennial International Conference on Healthcare-Associated Infections (ICHAI). Atlanta, GA, USA, 18–22 March 2010.
   Google Scholar
• McNeil S, Halperin SA, Hart R et al. Safety and immunogenicity of a novel hepatitis B vaccine adjuvanted with immunostimulatory sequence (ISS) in renal predialysis and dialysis patients. Presented at: National Kidney Foundation Spring Meetings. Orlando, FL, USA, 15–17 April 2010.
   Google Scholar
• Figueroa A. Dynavax and Merck provide update on US FDA clinical hold on investigational vaccine HEPLISAV™. In: Liver Disease/Hepatitis News – Medical News Today. Nordqvist C (Ed.). MediLexicon International Ltd, London, UK (2008).
   Google Scholar
• de Boer AW, McNeil S, Lunde N et al. Two clinical trials exploring safety and immunogenicity of a novel hepatitis B vaccine adjuvanted with immunostimulatory sequence in patients with chronic renal failure. Presented at: The 47th European Renal Association – European Dialysis and Transplant Association Joint Congress. Munich, Germany, 25–28 June 2010.
   Google Scholar
• McNeil S, Halperin SA, Hart R et al. Preliminary results from two studies comparing immunogenicity of three doses of HBsAg combined with immunostimulatory sequence (ISS) in chronic renal failure (CRF) patients. Presented at: 47th Annual Meeting of the Infectious Disease Society of America (IDSA). Philadelphia, PA, USA, 29 October–1 November 2009.
   Google Scholar
• Clarke T. FDA gives Dynavax OK to resume hepatitis B trials. In: Reuters. Lewis M (Ed.). Thomson Reuters, Boston, MA, USA (2009).
   Google Scholar
• Stynes T. Dynavax may seek FDA approval for heplisav earlier than expected. In: Company News. Newswires DJ (Eds). Dow Jones & Company, Inc., New York, NY, USA (2010).
   Google Scholar
• Ambrosch F, Wiedermann G, Kundi M et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine18(20), 2095–2101 (2000).
   PubMed Web of Science ®Google Scholar
• Andre FE, Safary A. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgrad. Med. J.63(Suppl. 2), 169–177 (1987).
   PubMed Web of Science ®Google Scholar
• Heineman TC, Clements-Mann ML, Poland GA et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine17(22), 2769–2778 (1999).
   PubMed Web of Science ®Google Scholar
• Cooper CL, Mills E, Angel JB. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. AIDS21(1), 71–76 (2007).
   PubMed Web of Science ®Google Scholar
• Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin. Infect. Dis.46(8), 1310–1314 (2008).
   PubMed Web of Science ®Google Scholar
• Mast EE, Weinbaum CM, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm. Rep.55(RR-16), 1–33 (2006).
   PubMedGoogle Scholar